Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Biobank initiatives are transforming how researchers understand dementia by collecting and analyzing brain tissue samples from people of different racial, ethnic, and genetic backgrounds. Rather than relying on tissue primarily from one demographic group, these initiatives recognize that dementia manifests differently across populations and may be influenced by genetic and environmental factors that vary by ancestry. The Accelerating Medicines Partnership in Alzheimer’s Disease (AMP-AD) Diversity Initiative exemplifies this approach—in October 2024, researchers completed the most comprehensive multi-omics profiling of brain tissue from Black American, Latin American, and non-Hispanic White donors, generating RNA sequencing, whole genome sequencing, and proteomics data that reveals how dementia-related changes appear across different genetic backgrounds.
For decades, neuroscience research relied heavily on brain tissue from predominantly white populations, creating a gap in understanding how dementia affects people of color and those with different genetic ancestry. This limitation meant that treatment approaches were often developed based on incomplete biological data. Biobank initiatives now systematically collect tissue from diverse donors with various cognitive conditions, making it possible to identify disease mechanisms that might be specific to certain populations or, conversely, to identify universal pathways that could lead to treatments effective for everyone.
Table of Contents
- Why Diverse Brain Tissue Samples Are Critical for Understanding Dementia Across All Populations
- Large-Scale Brain Tissue Collection: Current Initiatives and Their Scope
- From Laboratory Analysis to Scientific Discovery: How Brain Tissue Data Advances Dementia Research
- Expanding the Scope: Specialized Biobanks and Tailored Collection Efforts
- Data Accessibility and the Challenge of Sharing Research Resources
- Special Populations and the Push to Include Underrepresented Groups
- The Future of Brain Tissue Banking and Dementia Science
- Conclusion
Why Diverse Brain Tissue Samples Are Critical for Understanding Dementia Across All Populations
The biological reality is that dementia is not uniform across populations. Genetic risk factors for Alzheimer’s disease and other dementias vary significantly by ancestry, and environmental factors—including diet, education, socioeconomic status, and access to healthcare—interact with genetics in ways that differ across groups. When biobanks include only tissue from one demographic, researchers miss critical information about how these interactions shape disease development. A recent large-scale genetic characterization published in 2025 examined data from 25,001 dementia cases and 93,542 controls across 11 ancestries from five distinct biobanks. This analysis revealed genetic associations that appear in some populations but not others, underscoring why diversity in tissue collection is not a matter of representation alone—it is fundamental to understanding the biology of dementia itself. The AMP-AD program illustrates this principle through its decade-long effort.
Over the past ten years, researchers have profiled approximately 2,000 human brain samples, with earlier collections dominated by non-Hispanic white donors. The shift toward diversity has required deliberate effort to recruit donors from African American and Latin American communities. Now, with over 600 donors from these groups, researchers can directly compare molecular patterns in brain tissue across populations. For instance, some markers of neuroinflammation or tau pathology may appear at different levels or patterns depending on ancestry, which would never be apparent if all tissue came from a single group. Without diverse tissue samples, the field risks perpetuating a cycle where treatments developed from limited data work well for some populations but fail or perform differently for others. This is not hypothetical—it has happened before in medicine, where drugs were tested predominantly in certain groups and then discovered to have different efficacy or side effects in others.
Large-Scale Brain Tissue Collection: Current Initiatives and Their Scope
The NIH NeuroBioBank operates as a centralized resource, providing researchers with access to genome-wide genotyping and whole genome sequencing data from 9,667 subjects. This represents one of the largest open-access repositories of human brain tissue and associated genetic data available to the research community. Researchers can request tissue samples and corresponding data through a straightforward application process, accelerating studies that would otherwise require years of individual tissue procurement. The NeuroBioBank’s approach democratizes access to rare biological material, allowing smaller labs and researchers in underserved regions to participate in cutting-edge neuroscience research. However, a significant limitation remains: even with thousands of samples, achieving truly representative diversity is challenging.
The majority of samples in most biobanks still come from older populations (given that dementia is age-associated) and from regions with established research infrastructure, typically in North America and Europe. Additionally, the Down Syndrome Biobank Consortium, established with 11 sites across Europe, India, and the United States, demonstrates that specialized biobanks focusing on specific populations or conditions are essential because general biobanks may not accumulate enough tissue from a particular group to enable meaningful analysis. This specialization reflects a practical reality: simply having diverse tissue in a large collection does not guarantee it is sufficient for studying rare or underrepresented dementia subtypes. The financial and logistical demands of tissue collection should not be underestimated. Biobanks require freezers, trained personnel, quality control procedures, and secure data systems. Brain tissue, unlike blood samples, must be collected at autopsy or during rare neurosurgical procedures, limiting how quickly a biobank can expand.
From Laboratory Analysis to Scientific Discovery: How Brain Tissue Data Advances Dementia Research
Modern biobanks do not simply store tissue; they generate multi-omics data—meaning researchers extract and analyze RNA, proteins, metabolites, and genetic information from the same samples. The AMP-AD Diversity Initiative’s October 2024 results included tandem mass tag proteomics, a technique that measures thousands of proteins in brain tissue simultaneously. This approach reveals how protein levels and modifications differ across populations, which can explain differences in disease progression or treatment response. For example, if a particular inflammatory protein appears at higher baseline levels in one population’s brain tissue, it might suggest that treatments targeting inflammation could have different optimal doses for different groups. The scale of data generated is enormous. A single brain tissue sample can yield data on tens of thousands of genes and proteins.
When multiplied across thousands of samples, this creates a rich resource for discovering disease mechanisms. Researchers can ask questions like: “Which molecular changes appear in all people with Alzheimer’s, and which are specific to certain populations?” or “Do risk genes identified in one population show similar effects in another?” These questions could not be answered a decade ago because the tissue was not available. Now, they can be systematically addressed. The limitation here is that data generation does not automatically translate into therapeutic advances. The tools exist to measure molecular differences, but understanding which differences cause disease versus which are consequences remains a challenge. Additionally, tissue collected at autopsy represents the end-stage disease, not the beginning, so biobanks provide snapshots rather than the full progression of dementia in an individual.
Expanding the Scope: Specialized Biobanks and Tailored Collection Efforts
Beyond the large, general-purpose biobanks, specialized initiatives focus on specific populations or dementia types. The Down Syndrome Biobank Consortium represents an important example because people with Down syndrome have a very high risk of Alzheimer’s disease—nearly all develop amyloid pathology by age 40—yet their brain tissue has historically been scarce in research collections. By establishing eleven dedicated biobanking sites across three continents, the consortium enables researchers to study whether Alzheimer’s pathology in Down syndrome follows the same or different molecular pathways than in the general population. This specialization has a tradeoff: while it generates critical knowledge for a specific population, it requires additional funding and coordination separate from general biobanks. Another approach involves recruiting living donors willing to undergo brain imaging and cognitive testing, with tissue collection planned for the future.
This prospective strategy allows researchers to know donors’ detailed clinical histories before tissue becomes available, but it requires long-term follow-up and sustained funding. The Healthy Brain Initiative and the Building Our Largest Dementia Infrastructure (BOLD) awards exemplify this model. These initiatives have been extended through 2026, but the uncertain funding landscape beyond 2026 poses a risk to ongoing recruitment and follow-up efforts. The practical comparison is between rapid collection and detailed characterization. Large, rapidly assembled tissue collections may contain limited clinical data about each donor, whereas smaller, prospectively followed cohorts provide rich clinical information but accumulate tissue more slowly. The ideal approach combines both strategies—building large collections while maximizing the clinical data attached to each sample.
Data Accessibility and the Challenge of Sharing Research Resources
The NIH NeuroBioBank operates as an open-access resource, making genome data available to any qualified researcher, which accelerates science. However, access to actual brain tissue samples involves a more restricted process. Researchers must submit proposals explaining their intended use, and approval typically focuses on ensuring the research is scientifically sound and that tissue will be used responsibly. This gatekeeping serves important purposes—it prevents wasteful use of irreplaceable samples and ensures publications resulting from tissue use contribute to the scientific literature—but it also can slow research and may disadvantage researchers with less experience navigating the application process.
A warning worth noting: the pace of data generation now exceeds the capacity of the research community to analyze it. The AMP-AD program, for instance, has generated vast multi-omics datasets that are publicly available, yet many remain underutilized simply because analyzing such complex data requires specialized bioinformatics skills that are not universally available. This creates an equity gap where well-resourced labs can mine biobank data while smaller labs cannot, potentially concentrating the benefits of public collections in a few places. Additionally, the NIH NeuroBioBank itself faced maintenance and operational challenges, with scheduled maintenance periods affecting data access and sample availability. While routine maintenance is necessary, such disruptions highlight the infrastructure risks in relying on centralized biobanks.
Special Populations and the Push to Include Underrepresented Groups
The AMP-AD Diversity Initiative’s success in recruiting and profiling tissue from over 600 African American and Latin American donors represents a major shift from earlier decades when such representation was minimal. However, these donors still comprise a minority of the total 2,000 samples, indicating both progress and remaining work. The initiative deliberately partnered with minority-serving institutions and community organizations to build trust and facilitate recruitment, recognizing that historical medical abuses and ongoing disparities in healthcare create justified skepticism in these communities.
For example, researchers working with the initiative have published findings showing that genetic risk variants associated with Alzheimer’s disease differ in frequency across populations. Variants common in people of African ancestry sometimes have minimal association with disease risk, whereas different variants may be more relevant. Such discoveries have direct implications for genetic screening and risk prediction tools, which must be calibrated for the populations they will be applied to. Without tissue from these populations, risk prediction tools would systematically misclassify many people of color, potentially delaying diagnosis or prognosis.
The Future of Brain Tissue Banking and Dementia Science
As biobanks mature and diversify, the field is moving toward integration across resources. Researchers increasingly combine data from multiple biobanks, as reflected in the 2025 study that pooled information from five distinct biobanks. This meta-analytic approach provides the statistical power to detect subtle genetic effects that would not be visible in any single collection.
The extension of the Healthy Brain Initiative and BOLD awards through 2026 signals continued commitment, though uncertainty about future funding beyond that date creates challenges for long-term planning and sustained recruitment. Looking forward, emerging technologies like single-cell sequencing and spatial transcriptomics promise to reveal not just what molecules are present in brain tissue but exactly where in the tissue they are located and in which cell types. Applied to diverse biobank tissue, these methods could illuminate why dementia appears differently in different populations at the cellular level. The investments made in building diverse biobanks today are laying the groundwork for discoveries that will reshape dementia research and, ultimately, how the disease is treated.
Conclusion
Biobank initiatives collecting diverse brain tissue samples represent a fundamental shift in how dementia research is conducted. By moving beyond a reliance on tissue from predominantly white populations, these initiatives—led by the AMP-AD Diversity Initiative, NIH NeuroBioBank, and specialized efforts like the Down Syndrome Biobank Consortium—are generating multi-omics data that reveals both universal and population-specific mechanisms of dementia. The scale of collection is substantial: approximately 2,000 samples in AMP-AD, 9,667 subjects in the NeuroBioBank, and data from 25,001 cases and 93,542 controls across eleven ancestries in recent large studies.
The path forward requires sustained funding, continued recruitment from underrepresented communities, and integration of datasets across biobanks. For people concerned about dementia risk or diagnosis, these initiatives matter because they ensure that research discoveries and treatments will be based on biological understanding that encompasses their population. For researchers, access to diverse tissue is no longer a luxury—it is essential for conducting science that is both scientifically rigorous and equitable.
You Might Also Like
- The Brain Health Equity Initiative Working to Ensure Dementia Prevention Reaches Every Community Regardless of Income
- Why Your Neighborhood’s Green Space May Be Protecting Your Brain From Dementia Without You Knowing
- The Age Friendly Health System Movement That Is Retraining Doctors to Think About Brain Health First
